William Buck, MD
Family Medicine · Salina, KSNPI 1023060902
Payments from drug & device makers
Across 378 payments — averaging $14.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$944
- Amgen$780
- Lilly USA, LLC$540
- Novo Nordisk$523
- AbbVie$405
- AstraZeneca$276
- plus $2K from 33 others
What the payments were for
- Food & beverage$5,51298%
- Education$1142%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 60 | $944 |
| Amgen | 60 | $780 |
| Lilly USA, LLC | 44 | $540 |
| Novo Nordisk | 40 | $523 |
| AbbVie(2 entities) | 23 | $405 |
| AstraZeneca(2 entities) | 18 | $276 |
| Johnson & Johnson | 17 | $265 |
| Astellas Pharma US Inc | 16 | $262 |
| Novartis | 13 | $211 |
| Bayer | 8 | $172 |
| Otsuka America Pharmaceutical, Inc. | 7 | $138 |
| Sanofi | 8 | $133 |
| Sanofi-aventis U.S. LLC | 8 | $106 |
| GSK | 7 | $104 |
| Merck | 6 | $81 |
| Esperion Therapeutics, Inc. | 4 | $80 |
| Grifols USA, LLC | 4 | $71 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $57 |
| Boehringer Ingelheim | 4 | $54 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $49 |
| Mallinckrodt Hospital Products Inc. | 2 | $44 |
| Fresenius USA Marketing, Inc. | 2 | $38 |
| Viiv Healthcare Company | 2 | $28 |
| E.r. Squibb & Sons, L.L.C. | 2 | $25 |
| Seqirus USA Inc | 1 | $25 |
| Shire North American Group Inc | 2 | $23 |
| Sanofi Pasteur Inc. | 1 | $18 |
| Exact Sciences | 1 | $18 |
| Alnylam Pharmaceuticals Inc. | 1 | $17 |
| Ultragenyx Pharmaceutical Inc. | 1 | $17 |
| Corium, LLC | 1 | $17 |
| Abbott | 1 | $16 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $14 |
| Xeris Pharmaceuticals, Inc. | 1 | $13 |
| OPKO Pharmaceuticals, LLC | 1 | $13 |
| Vifor Pharma, Inc. | 1 | $13 |
| Dexcom, Inc. | 1 | $12 |
| Mylan Specialty L.p. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PREVNAR 20$102
- COMIRNATY$102
- PENBRAYA$102
How this compares
$5,626 in reported general payments places this provider in the 85th percentile of 1,469 family medicine providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 227 | $169,704 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 119 | $112,858 |
| JardianceEmpagliflozin | 130 | $95,929 |
| OzempicSemaglutide | 73 | $89,869 |
| XareltoRivaroxaban | 107 | $76,685 |
| TrulicityDulaglutide | 41 | $40,579 |
| MyrbetriqMirabegron | 38 | $23,102 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 62 | $19,588 |
| JanuviaSitagliptin Phosphate | 27 | $18,151 |
| EntrestoSacubitril/Valsartan | 15 | $15,500 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 57 | $12,565 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 17 | $10,618 |
| Tresiba Flextouch U-100Insulin Degludec | 21 | $9,548 |
| Varenicline Tartrate | 33 | $8,138 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 12 | $8,106 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Abrysvo | $944 | $189,292289 claims |
| Boehringer IngelheimJardiance, Combivent Respimat, Spiriva Respimat, Tradjenta | $54 | $118,525171 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $106 | $112,858119 claims |
| Novo NordiskOzempic | $523 | $89,86973 claims |
| Johnson & JohnsonXarelto, Invokana | $265 | $82,878118 claims |
| Lilly USA, LLCTrulicity | $540 | $40,57941 claims |
| GSKShingrix, Trelegy Ellipta, Incruse Ellipta | $104 | $26,93885 claims |
| Astellas Pharma US IncMyrbetriq | $262 | $23,10238 claims |
| MerckJanuvia | $81 | $18,15127 claims |
| NovartisEntresto | $211 | $15,50015 claims |
| AstraZenecaSymbicort | $276 | $5,41716 claims |
| AbbVieSynthroid | $405 | $1,97123 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,469 family medicine providers in Kansas.
Other family medicine in Salina
- Son NguyenSalina$17K
- Terry PolingWichita$24.2M
- Richard GloverNewton$19.6M
- Daniel DickersonLenexa$13.6M
- Patrick YaoOlathe$11.7M
- Michael RauschAugusta$8.1M
- Terry KleinWichita$5.9M
- Richard EgelhofWichita$4.1M
- Thomas KleinWichita$3.4M
- Troy HoldemanNewton$3.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.